Baxter International (BAX) Faces Tough Road Ahead, Says Citi in Downgrade

With a TTM operating cash flow of $1.25 billion, Baxter International Inc. (NYSE:BAX) is included among the 12 Cash-Rich Stocks to Buy Right Now.

On May 28, Citi analyst Joanne Wuensch downgraded Baxter International Inc. (NYSE:BAX) to Sell from Neutral. She lowered the price target on the stock to $17 from $19. In a research note, the analyst said the company faces a year that is weighted toward the second half and is still searching for a CFO. Citi also noted that valuations across the broader medical technology sector are “dipping into value territory,” which it believes offers investors more attractive opportunities than Baxter.

On May 4, Barclays raised its price recommendation on Baxter to $27 from $25. It reiterated an Overweight rating on the shares. The analyst said the company exceeded expectations at a time when many investors had anticipated a guidance cut. In a research note, Barclays described the results as a “respectable beat and reiterated outlook.”

Baxter International Inc. (NYSE:BAX) is a global medical technology company. Its operations are organized into three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals.

READ NEXT: 10 Most Profitable Dividend Stocks to Invest In Now and 10 Best Dividend Stocks to Buy According to D. E. Shaw

Disclosure: None. Follow Insider Monkey on Google News.